Lipus

Lovastatin, the active ingredient in Lipus, is a HMG‑CoA reductase inhibitor presented as an oral tablet for oral use. It lowers elevated blood cholesterol levels and is prescribed for patients with hypercholesterolemia, primary hyperlipidemia, or at risk of cardiovascular disease.

GNH USA supplies Lipus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing consistent quality and regulatory compliance, adheres to EU GMP standards and offers reliable logistics for global distribution, and supports regulatory approvals in target markets.

Lovastatin is used to treat disorders of lipid metabolism and to reduce cardiovascular risk.

- Hypercholesterolemia: reduces total and LDL cholesterol levels, helping to achieve target lipid goals. - Primary hyperlipidemia: lowers elevated plasma lipids, improving lipid profile in patients with familial or secondary dyslipidemia. - Prevention of cardiovascular disease: decreases risk of myocardial infarction and stroke by managing cholesterol in at‑risk individuals.

Lovastatin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate head pain. - Indigestion: gastrointestinal discomfort or dyspepsia. - Muscle aches: mild myalgia without weakness.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown that can cause kidney injury. - Severe liver injury: marked elevation of transaminases with possible jaundice. - Allergic reactions: rash, pruritus, or angioedema. - Myopathy with weakness: significant muscle weakness affecting daily activities.

When prescribing Lipus, clinicians should observe several safety measures.

- Baseline assessment: obtain liver function tests before initiating therapy. - Monitoring: repeat liver enzymes periodically, especially after dose changes. - Drug interactions: avoid concomitant use with strong CYP3A4 inhibitors. - Pregnancy: contraindicated; do not prescribe to pregnant women (Category X). - Lactation: discontinue if breastfeeding, as drug may be excreted in milk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Lovastatin interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): can markedly increase lovastatin levels. - Gemfibrozil: synergistic effect raises risk of myopathy. - Antacids containing aluminum or magnesium: may reduce absorption of lovastatin.

Moderate Interactions (Monitor Closely): - Grapefruit juice: can increase lovastatin concentration, monitor for muscle symptoms. - Cyclosporine: may elevate statin levels, consider dose adjustment. - Warfarin: may enhance anticoagulant effect, monitor INR.